Your browser doesn't support javascript.
loading
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies.
Barrios, D M; Phillips, G S; Geisler, A N; Trelles, S R; Markova, A; Noor, S J; Quigley, E A; Haliasos, H C; Moy, A P; Schram, A M; Bromberg, J; Funt, S A; Voss, M H; Drilon, A; Hellmann, M D; Comen, E A; Narala, S; Patel, A B; Wetzel, M; Jung, J Y; Leung, D Y M; Lacouture, M E.
Affiliation
  • Barrios DM; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
  • Phillips GS; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
  • Geisler AN; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
  • Trelles SR; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
  • Markova A; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Dermatology, Weill Cornell Medicine, New York, USA.
  • Noor SJ; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Dermatology, Weill Cornell Medicine, New York, USA.
  • Quigley EA; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Dermatology, Weill Cornell Medicine, New York, USA.
  • Haliasos HC; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Dermatology, Weill Cornell Medicine, New York, USA.
  • Moy AP; Department of Dermatology, Weill Cornell Medicine, New York, USA; Dermatopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA.
  • Schram AM; Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medicine, New York, USA.
  • Bromberg J; Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medicine, New York, USA.
  • Funt SA; Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medicine, New York, USA.
  • Voss MH; Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medicine, New York, USA.
  • Drilon A; Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medicine, New York, USA.
  • Hellmann MD; Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medicine, New York, USA.
  • Comen EA; Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medicine, New York, USA.
  • Narala S; Department of Dermatology, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, USA.
  • Patel AB; Department of Dermatology, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, USA.
  • Wetzel M; Division of Dermatology, Department of Medicine, University of Louisville School of Medicine, Louisville, USA.
  • Jung JY; Division of Dermatology, Department of Medicine, University of Louisville School of Medicine, Louisville, USA; Dermatology Service, Department of Medical Oncology, Norton Cancer Institute, Louisville, USA.
  • Leung DYM; Department of Pediatrics, National Jewish Health, Denver, USA.
  • Lacouture ME; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Dermatology, Weill Cornell Medicine, New York, USA. Electronic address: LacoutuM@mskcc.org.
Ann Oncol ; 32(6): 736-745, 2021 06.
Article in En | MEDLINE | ID: mdl-33667669
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoglobulin E / Omalizumab Type of study: Observational_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male Language: En Journal: Ann Oncol Year: 2021 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoglobulin E / Omalizumab Type of study: Observational_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male Language: En Journal: Ann Oncol Year: 2021 Document type: Article